RVV — Revive Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$8.71m
- CA$8.71m
Brief: Revive Therapeutics inititates Phase 2 study of revenue-004 (bucillamine) in cystinuria
Brief: Revive Therapeutics engages Massachusetts General Hospital for cystinuria phase 2 study
Brief: Revive Therapeutics announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria
Brief: Revive Therapeutics announces US FDA acceptance
Brief: Revive Therapeutics appoints Craig Leon as CEO
Brief: Revive announces completion of rights offering
Brief: Revive Therapeutics announces rights offering to fund clinical development of Bucillamine
Brief: Revive to start Phase 2b trial in gout after access to required capital
Brief: Revive Therapeutics provides clinical and corporate update